Cancer Biomarkers Market Size, Share & Industry Analysis, By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, and Others), By Biomarker Type (PSA, HER-2, EGFR, KRAS, and Others), By End User (Pharmaceutical & Biotechnology Companies, Diagnostics & Research Laboratories, Hospitals & Specialty Clinics, and Others), and Regional Forecast, 2019-2032

The global cancer biomarkers market size was valued at USD 18.94 billion in 2018 and is projected to reach USD 97.42 billion by 2032, exhibiting a CAGR of 12.4% during the forecast period. North America dominated the global market with a share of 36.33% in 2018.

The increasing global incidence of cancer, expanding research on cancer biomarkers, expanding use of biomarkers in drug development and discovery, and technological advancements are the main factors propelling this cancer biomarkers market's growth. 

Biomarkers in oncology are the molecules secreted by a tumor or a specific response of the human body, indicating the presence of cancer. Biomarkers enable cancer detection at an early stage and facilitate high-speed noninvasive diagnosis using various genomics and proteomics tools. Biomarkers are used for various applications such as cancer diagnostics, drug discovery and development, prognostics, personalized medicine, and others. Additionally, the increasing demand for biomarkers in drug discovery and development for personalized medicine, is boosting the growth of the global market.

Research collaborations by various institutions and key market players with an aim to develop biomarkers for disease diagnosis is one of the major factor anticipated to upsurge the cancer biomarkers market growth. For instance, in May 2019, Biotech Support Group (BSG) entered into a research collaboration with Leiden University Medical Center (LUMC) with an aim to develop Stromal conditioning biomarkers in cancer (protein biomarker).

MARKET TRENDS

The Paradigm Shift towards Personalized Medicine for Cancer Treatment is Fueling the Demand for Cancer Biomarkers

The paradigm shifts towards personalized medicine for cancer treatment due to lack of standard diagnosis and treatment is one of the major factor anticipated to increase demand for cancer biomarkers. Additionally, the importance of biomarkers is increasing in the field of personalized medicine, with applications in diagnosis, prognosis, and selection of targeted therapies. Collaborations of various key market players with research institutes with an aim to develop novel cancer biomarkers for personalized medicine is also one of the major element anticipated to drive the market growth during the forecast period.

The continuous development and identification of biomarkers specific to the disease and individual patients are vigorous for personalized medicine, and biomarkers play a vital role in terms of calculating disease risk and response to therapy. Thus, the field of personalized medicine is expected to offer impending growth opportunities for players operating in the oncology biomarkers market.

MARKET DRIVERS

Rising Prevalence of Cancer to Fuel Market Growth

Cancer biomarkers are prominently used in companion diagnostics, personalized medicines, and other disease diagnostics, including disease risk assessment and drug discovery and development. The rising adoption of biomarkers in disease diagnostics is one of the major factors expected to drive cancer biomarkers market growth during the forecast period of 2019-2026.

Rising prevalence of cancer globally, leading to increasing demand for the early disease diagnosis, subsequently propelling the growth of the market. For instance, the National Cancer Institute, in 2018, an estimated 1,735,350 new cases of cancer were diagnosed in the United States. Additionally, according to the World Cancer Research Fund International, an estimated 18.0 million people were suffering from globally in 2018. Lung and breast cancers were the most common cancers reported globally, contributing to 12.3% of the total number of the cases diagnosed in 2018.

The rising prevalence of cancer biomarkers in emerging and developed countries is anticipated to increase the demand for cancer diagnostics and treatment. These factors are anticipated to propel the demand for these biomarkers during the forecast period of 2019-2026.

Presence of Potential Pipeline Candidates to Boost the Market

Many pharmaceutical companies are actively investing in research and development of novel biomarkers for the diagnosis and treatment of cancer. Many potential candidates are in their end stages of development and are projected to give a tremendous boost to the market after their launch.

According to the U.S. National Library of Medicine, around 1,515 cancer biomarkers are under clinical trials.  For instance, Lund University Hospital in collaboration with South Sweden Breast Cancer Group is currently conducting clinical trials to compare the efficacy and tolerability of atorvastatin (in phase 2). This is evaluated against resistance to endocrine treatment (Fulvestrant/Aromatase Inhibitors) in patients with advanced breast cancer (ABC-SE). The study is estimated to be accomplished by April 2022. The introduction of new biomarkers for cancer screening and diagnosis during the forecast period is anticipated to propel the oncology biomarkers market growth.

MARKET RESTRAINT

Lack of Reimbursement Policies for Biomarker Testing is one of factor Limiting Use of Cancer Biomarkers

Despite the increasing incidence of cancer globally, and growing number of patients requiring diagnostic tests, lack of reimbursement policies for biomarker tests in emerging and developed countries, is one of the factor that is limiting the demand for these biomarkers globally. Another major factor restricting the growth of the market is the high cost for diagnosis and treatment for cancer in emerging countries. This is limiting the number of patients undergoing biomarker testing, and growing preference of patients towards other low-cost detection tests.

SEGMENTATION

By Cancer Type Analysis

Lung Cancer Segment is anticipated to grow at Significant CAGR

Based on type, the market is segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, and others. The breast cancer segment dominated the oncology biomarkers market in 2018. Increasing prevalence of breast cancer, coupled with the rise in awareness about breast cancer diagnosis are factors presenting large patient pool undergoing diagnostic tests. This coupled with, rising research activities focusing on new biomarkers for detection of breast cancer are some of the major factors driving the breast cancer segment growth. However, the lung cancer segment is anticipated to grow at a significant CAGR during the forecast period of 2019-2026. This is attributable to the rising investment into research & development of biomarkers for lung cancer by key market players.

By Biomarker Type Analysis

EGFR Biomarker to Grow at Significant CAGR during Forecast Period of 2019-2026

Based on biomarker type, the market is segmented into PSA, HER-2, EGFR, KRAS and others. HER-2 segment held the largest share in 2018 due to the rising prevalence of breast cancer and increasing awareness about disease diagnosis in both developed and developing countries. This along with new biomarker based tests being introduced by market players for breast cancer diagnosis, based on liquid biopsy is propelling the demand for these tests globally. However, the EGFR biomarker segment is anticipated to grow at a faster pace due to the rising prevalence of lung cancer and increasing demand for diagnosis. For instance, according to the American Cancer Society, an approximate of 234,030 new cases of lung cancer were reported in the United States in 2018.

By End User Analysis

Increasing Use of Biomarkers for Drug Discovery and Development to Fuel Growth of Pharmaceutical & Biotechnology Companies Segment

Based on end user, the market is segmented into pharmaceutical & biotechnology companies, diagnostics & research laboratories, hospitals & specialty clinics and others. Among end users, the diagnostics & research laboratories segment held the dominant cancer biomarkers market share. The introduction of new products for diagnosis is one of the additional factor driving the segment growth. For instance, QIAGEN launched Therascreen PIK3CA RGQ PCR Kit, in May 2019 to identify detect breast cancer patients who are eligible for treatment through PIQRAY – a first and only approved treatment for PIK3CA mutation in breast cancer. Additionally, the test kit is the first FDA approved assay which uses plasma specimen as a liquid biopsy to guide treatment decisions in breast cancer.

The increasing investment by key market players, and growing importance of biomarker tests in drug discovery and development, is one factor propelling the demand for cancer biomarkers from pharmaceutical & biotechnology companies. Growing number of tests being performed at hospitals for inpatients suffering from various cancers, is driving the growth of the hospitals & specialty clinics segment.

REGIONAL ANALYSIS

Cancer biomarkers market in North America was valued at USD 6.88 billion in 2018. North America dominated the global market followed by Europe. Major factors attributed to dominance of North America include, higher adoption of advanced technologies like next-generation sequencing, and the increasing number of research studies establishing the efficiency of biomarkers in drug discovery and development, and cancer diagnosis. Asia Pacific is anticipated to grow at a significant CAGR during the forecast period due to growing adoption of biomarker based tests for cancer diagnosis, along with adoption of technologically advanced instruments by laboratories in the region. Additionally, rising funding and investments from public and private organizations in research and development of biomarkers, and the use of biomarkers in patient stratification and drug development process are some of the factors anticipated to drive the growth of the market in the region. Additionally, rising prevalence of cancer in emerging countries and increasing awareness about biomarkers tests in diagnostics are some of the major factors anticipated to drive the market growth in Latin America and the Middle East & Africa during the forecast period.

KEY INDUSTRY PLAYERS

F. Hoffmann-La Roche Ltd., Abbott, and Thermo Fisher Scientific, Inc. are Leading Market Players

The cancer biomarkers market is a semi-consolidated market. To strengthen their position, key market players are focusing on the introduction of novel biomarker tests, and mergers & acquisitions with other prominent companies with an aim to establish a strong brand presence. For instance, in November 2016, Thermo Fisher Scientific Inc., launched four new additions to its product portfolio of multi-biomarker targeted assays. This includes the Oncomine Immune Response Research Assay, which is designed to cross-examine the microenvironment of the tumor and allow further identification of prognostic biomarkers.

F. Hoffmann-La Roche Ltd., Abbott, and Thermo Fisher Scientific, Inc. are among the top market players in the global oncology biomarkers market. Other players operating in the market are Bio-Rad Laboratories, Inc., Sino Biological Inc., BioVision Inc., Myriad RBM, R&D System, Axon Medchem, CENTOGENE N.V., and others.

LIST OF KEY COMPANIES PROFILED:

• F. Hoffmann-La Roche Ltd.


•  Abbott


• Thermo Fisher Scientific


•  Bio-Rad Laboratories, Inc.


•  CENTOGENE N.V.


•  Axon Medchem


• Sino Biological Inc.


• R&D System


• BioVision Inc.


• Myriad RBM


• Other players

KEY INDUSTRY DEVELOPMENTS: 

• March 2021- Roche made an announcement that company has received the approval from US Food and Drug Administration for VENTANA ALK (D5F3) CDx Assay as a companion diagnostic. This assay test is the only test which was approved by FDA for as a companion diagnostic for LORBRENA and will help in identifying patients with this cancer biomarker quickly so they can be given more effective treatment.


• July 2020 - Thermo Fisher Scientific has announced that the company has signed a companion diagnostic (CDx) agreement with Chugai Pharmaceutical Co., Ltd., and has applied to the Ministry of Health, Labour and Welfare (MHLW) to increase the use of the Oncomine Dx Target Test in Japan. This agreement focuses on accelerating the local biomarker testing of NSCLC patients eligible for entrectinib in Japan.


• November 2020 - Agilent Technologies Inc. made an announcement of the launch of the Biomarker Pathologist Training Program which is a worldwide initiative built to enable pathologists to score biomarkers precisely. The program initially was available in Europe and North America, along with China and Asia which utilizes a digital platform.

REPORT COVERAGE

The cancer biomarkers market report provides a detailed analysis of the market and focuses on key aspects such as leading companies, cancer type, and leading biomarker types. Besides, the report offers insights into the market, current trends and highlights key industry developments. In addition to the aforementioned factors, the report encompasses several factors that have contributed to the growth of the market over recent years.

Report Scope & Segmentation